Back to Search Start Over

Genome-wide association study reveals novel genetic loci

Authors :
Carolina Roselli
Mengyao Yu
Victor Nauffal
Adrien Georges
Qiong Yang
Katie Love
Lu Chen Weng
Francesca N Delling
Svetlana R Maurya
Maren Schrölkamp
Jacob Tfelt-Hansen
Albert Hagège
Xavier Jeunemaitre
Stéphanie Debette
Philippe Amouyel
Wyliena Guan
Jochen D Muehlschlegel
Simon C Body
Svati Shah
Zainab Samad
Sergiy Kyryachenko
Carol Haynes
Michiel Rienstra
Thierry Le Tourneau
Vincent Probst
Ronan Roussel
Inez J Wijdh-Den Hamer
Joylene E Siland
Kirk U Knowlton
Jean Jacques Schott
Robert A Levine
Emelia J Benjamin
Ramachandran S Vasan
Benjamin D Horne
Joseph B Muhlestein
Giovanni Benfari
Maurice Enriquez-Sarano
Andrea Natale
Sanghamitra Mohanty
Chintan Trivedi
Moore B Shoemaker
Zachary T Yoneda
Quinn S Wells
Michael T Baker
Eric Farber-Eger
Hector I Michelena
Alicia Lundby
Russell A Norris
Susan A Slaugenhaupt
Christian Dina
Steven A Lubitz
Nabila Bouatia-Naji
Patrick T Ellinor
David J Milan
Cardiovascular Centre (CVC)
Source :
Eur Heart J, European Heart Journal, 43(17), 1668-1680. Oxford University Press
Publication Year :
2022

Abstract

AIMS: Mitral valve prolapse (MVP) is a common valvular heart disease with a prevalence of >2% in the general adult population. Despite this high incidence, there is a limited understanding of the molecular mechanism of this disease, and no medical therapy is available for this disease. We aimed to elucidate the genetic basis of MVP in order to better understand this complex disorder.METHODS AND RESULTS: We performed a meta-analysis of six genome-wide association studies that included 4884 cases and 434 649 controls. We identified 14 loci associated with MVP in our primary analysis and 2 additional loci associated with a subset of the samples that additionally underwent mitral valve surgery. Integration of epigenetic, transcriptional, and proteomic data identified candidate MVP genes including LMCD1, SPTBN1, LTBP2, TGFB2, NMB, and ALPK3. We created a polygenic risk score (PRS) for MVP and showed an improved MVP risk prediction beyond age, sex, and clinical risk factors.CONCLUSION: We identified 14 genetic loci that are associated with MVP. Multiple analyses identified candidate genes including two transforming growth factor-β signalling molecules and spectrin β. We present the first PRS for MVP that could eventually aid risk stratification of patients for MVP screening in a clinical setting. These findings advance our understanding of this common valvular heart disease and may reveal novel therapeutic targets for intervention.KEY QUESTION: Expand our understanding of the genetic basis for mitral valve prolapse (MVP). Uncover relevant pathways and target genes for MVP pathophysiology. Leverage genetic data for MVP risk prediction.KEY FINDING: Sixteen genetic loci were significantly associated with MVP, including 13 novel loci. Interesting target genes at these loci included LTBP2, TGFB2, ALKP3, BAG3, RBM20, and SPTBN1. A risk score including clinical factors and a polygenic risk score, performed best at predicting MVP, with an area under the receiver operating characteristics curve of 0.677.TAKE-HOME MESSAGE: Mitral valve prolapse has a polygenic basis: many genetic variants cumulatively influence pre-disposition for disease. Disease risk may be modulated via changes to transforming growth factor-β signalling, the cytoskeleton, as well as cardiomyopathy pathways. Polygenic risk scores could enhance the MVP risk prediction.

Details

Language :
English
ISSN :
0195668X
Volume :
43
Issue :
17
Database :
OpenAIRE
Journal :
European Heart Journal
Accession number :
edsair.doi.dedup.....30eee9c44c658bdf1334d9d5447132ce